Literature DB >> 15370246

Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia.

James B Johnston1, James T Paul, Nathan J Neufeld, Neil Haney, Dianne M Kropp, Xiaojie Hu, Mary Cheang, Spencer B Gibson.   

Abstract

The primary abnormality in chronic lymphocytic leukemia (CLL) is a defect in apoptosis, probably related to alterations in the expressions of Bcl-2 family members. In transgenic mice over expressing the anti-apoptotic Bcl-2 family member, myeloid cell factor-1 (Mcl-1), B cell lymphomas occur. Moreover, mice conditional for the loss of Mcl-1 display a profound reduction in B and T lymphocytes. This suggests that Mcl-1 is an essential survival factor in lymphocytes. In the present study, we have evaluated the role of Mcl-1 in CLL. Mcl-1 protein expression was measured by Western blot analysis in the CLL cells of 45 patients and correlated with clinical variables and survival. Mcl-1 levels were similar in 29 patients to normal B and T lymphocytes, were decreased in 8 patients and increased in 12 patients. An inverse correlation was found between Mcl-1 expression and Rai stage (P = 0.001). When assessed by flow cytometry, Mcl-1 expressions were normally distributed among CLL cells in individual patients and the mean levels correlated with those obtained by Western blotting. To evaluate the role of Mcl-1 in drug resistance, Mcl-1 levels were sequentially measured in the leukemic cells of 4 CLL patients during therapy with fludarabine (Flu). The Mcl-1 levels were found to increase in 2 patients while the peripheral blood lymphocyte counts dropped, suggesting that the residual drug-resistant cells had the highest Mcl-1 levels. Primary CLL cells were also treated with chlorambucil (CLB) or Flu in vitro and the Mcl-1 levels decreased correlating with the sensitivity of these cells to undergo apoptosis. Drug sensitivities of the CLL cells to CLB and Flu were also measured by MTT assay and the concentrations of drug required to decrease cell viability by 50% (IC50) varied from 1.9 to 9.27 microM for Flu (median, 9.4 microM) and 10 to 32.5 microM (median, 5.5 microM) for CLB. The sensitivities of the leukemic cells to CLB correlated inversely with Mcl-1 levels (P < 0.05). These results suggest that Mcl-1 may contribute to cell survival in CLL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15370246     DOI: 10.1080/10428190410001723317

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  8 in total

Review 1.  Chemosensitization of prostate cancer by modulating Bcl-2 family proteins.

Authors:  David Karnak; Liang Xu
Journal:  Curr Drug Targets       Date:  2010-06       Impact factor: 3.465

2.  Myeloid cell leukaemia 1 has a vital role in retinoic acid-mediated protection of Toll-like receptor 9-stimulated B cells from spontaneous and DNA damage-induced apoptosis.

Authors:  Kristine L Holm; Randi L Indrevaer; June Helen Myklebust; Arne Kolstad; Jan Øivind Moskaug; Elin H Naderi; Heidi K Blomhoff
Journal:  Immunology       Date:  2016-07-25       Impact factor: 7.397

3.  VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia.

Authors:  Sara Samuel; Vanessa F Tumilasci; Stephanie Oliere; Thi Liên-Anh Nguyên; April Shamy; John Bell; John Hiscott
Journal:  Mol Ther       Date:  2010-09-14       Impact factor: 11.454

4.  MiR-15a and miR-16-1 cluster functions in human leukemia.

Authors:  George A Calin; Amelia Cimmino; Muller Fabbri; Manuela Ferracin; Sylwia E Wojcik; Masayoshi Shimizu; Cristian Taccioli; Nicola Zanesi; Ramiro Garzon; Rami I Aqeilan; Hansjuerg Alder; Stefano Volinia; Laura Rassenti; Xiuping Liu; Chang-Gong Liu; Thomas J Kipps; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-24       Impact factor: 11.205

5.  Interplay between HIV-1 infection and host microRNAs.

Authors:  Guihua Sun; Haitang Li; Xiwei Wu; Maricela Covarrubias; Lisa Scherer; Keith Meinking; Brian Luk; Pritsana Chomchan; Jessica Alluin; Adrian F Gombart; John J Rossi
Journal:  Nucleic Acids Res       Date:  2011-11-10       Impact factor: 16.971

6.  Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.

Authors:  Annalisa Lonetti; Alessandra Cappellini; Alice Bertaina; Franco Locatelli; Andrea Pession; Francesca Buontempo; Camilla Evangelisti; Cecilia Evangelisti; Ester Orsini; Laura Zambonin; Luca Maria Neri; Alberto Maria Martelli; Francesca Chiarini
Journal:  J Hematol Oncol       Date:  2016-10-24       Impact factor: 17.388

7.  Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia.

Authors:  A Olsson; M Norberg; A Okvist; K Derkow; A Choudhury; G Tobin; F Celsing; A Osterborg; R Rosenquist; M Jondal; L M Osorio
Journal:  Br J Cancer       Date:  2007-08-28       Impact factor: 7.640

Review 8.  Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?

Authors:  S Baig; I Seevasant; J Mohamad; A Mukheem; H Z Huri; T Kamarul
Journal:  Cell Death Dis       Date:  2016-01-14       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.